Company: PCRX
Filing Date: 2025-03-14
Form Type: DFAN14A
Source: 0000921895-25-000772
Chunk: 3

Company: Pacira BioSciences, Inc.
Filing Date: 2025-03-14
Form: DFAN14A
Chunk 3
---
S WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS
IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES
SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.

The participants in the proxy solicitation
are anticipated to be DOMA, DOMA Perpetual LO Equity Master Fund LP, an exempted limited partnership organized under the laws of the
Cayman Islands (“DOMA LO Master”), DOMA Perpetual Partners GP LLC, a Delaware limited liability company (“DOMA GP”),
Joseph Kromholz, Philip Pucciarelli and Eric de Armas.

As of the date hereof, DOMA LO Master directly
beneficially owns 1,804,069 shares of Common Stock, par value $0.001 par value per share, of the Company (the “Common Stock”).
As of the date hereof, Pedro Escudero directly beneficially owns 159,000 shares of Common Stock. As of the date hereof, Mr. de Armas directly
beneficially owns 1,389 shares of Common Stock. As Investment Manager of DOMA LO Master, DOMA may be deemed to beneficially own the 1,804,069
shares of Common Stock beneficially owned by DOMA LO Master. As general partner of DOMA LO Master, DOMA GP may be deemed to beneficially
own the 1,804,069 shares of Common Stock beneficially owned by DOMA LO Master. As Founder and Chief Investment Officer of DOMA and Managing
Member of DOMA GP, Mr. Escudero may be deemed to beneficially own the 1,804,069 shares of Common Stock beneficially owned by DOMA and
DOMA GP. As of the date hereof, neither Messrs. Kromholz nor Pucciarelli beneficially own any shares of Common Stock.

Disclaimer

This letter has been prepared by DOMA. The
views expressed herein reflect the opinions of DOMA and are based on publicly available information with respect to Pacira BioSciences,
Inc. (“Pacira” or the “Company”). DOMA recognizes that there may be confidential information in the possession
of the Company that could lead it or others to disagree with DOMA’s conclusions